EDMONTON, June 27 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today the
enrolment of the last patient in its Phase 2b trial assessing ISA247 for the
prevention of kidney graft rejection following transplantation. Of the 332
patients enrolled, 148 patients have already completed the required six months
of treatment. The Company expects to have the last patient complete the six
months of active treatment before the end of the year. Furthermore, 43
patients have so far completed an additional 6 months of treatment in the
optional extension phase of this trial. As previously announced, Health Canada
granted a No Objection Letter allowing patients who have already completed 12
months of ISA247 treatment to continue therapy through to commercialization of
the drug.
